Jump Financial LLC Acquires 37,935 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Jump Financial LLC lifted its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 318.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,865 shares of the company’s stock after purchasing an additional 37,935 shares during the period. Jump Financial LLC’s holdings in PROCEPT BioRobotics were worth $4,015,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. FMR LLC lifted its stake in PROCEPT BioRobotics by 11.9% in the fourth quarter. FMR LLC now owns 8,159,208 shares of the company’s stock valued at $656,979,000 after buying an additional 866,328 shares during the period. Vanguard Group Inc. lifted its position in shares of PROCEPT BioRobotics by 6.1% during the 4th quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company’s stock valued at $413,907,000 after acquiring an additional 297,075 shares during the period. Alliancebernstein L.P. boosted its stake in PROCEPT BioRobotics by 14.2% during the fourth quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company’s stock worth $141,110,000 after acquiring an additional 218,148 shares in the last quarter. Wellington Management Group LLP boosted its stake in PROCEPT BioRobotics by 38.8% during the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company’s stock worth $120,051,000 after acquiring an additional 416,819 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in PROCEPT BioRobotics by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 1,164,037 shares of the company’s stock valued at $93,751,000 after purchasing an additional 57,449 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

Insider Activity

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the transaction, the chief executive officer now directly owns 173,070 shares in the company, valued at $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Waters sold 733 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares of the company’s stock, valued at $6,161,966.46. This represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock valued at $368,322 over the last three months. Corporate insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Stock Down 0.2 %

PRCT stock opened at $52.81 on Thursday. The stock’s 50 day moving average is $60.08 and its 200-day moving average is $75.17. PROCEPT BioRobotics Co. has a twelve month low of $47.04 and a twelve month high of $103.81. The firm has a market capitalization of $2.89 billion, a PE ratio of -27.08 and a beta of 1.09. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The firm had revenue of $68.24 million for the quarter, compared to analysts’ expectations of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. Sell-side analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Truist Financial reduced their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, April 11th. Morgan Stanley decreased their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $91.43.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).